Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BridgeBio Pharma Inc

Current price
24.74 USD -0.14 USD (-0.56%)
Last closed 24.95 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 948 847 104 USD
Yield for 12 month +50.21 %
21.11.2021 - 28.11.2021

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California. Address: 3160 Porter Drive, Palo Alto, CA, United States, 94304

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

49 USD

P/E ratio

Dividend Yield

Current Year

+9 303 000 USD

Last Year

+77 648 000 USD

Current Quarter

+1 745 000 USD

Last Quarter

+4 091 000 USD

Current Year

+6 857 000 USD

Last Year

+74 214 000 USD

Current Quarter

+1 147 000 USD

Last Quarter

+3 493 000 USD

Key Figures BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -592 950 016 USD
Operating Margin TTM -10123.9 %
PE Ratio
Return On Assets TTM -64.08 %
PEG Ratio
Return On Equity TTM -1789.67 %
Wall Street Target Price 49 USD
Revenue TTM 9 303 000 USD
Book Value -7.74 USD
Revenue Per Share TTM 0.057 USD
Dividend Share
Quarterly Revenue Growth YOY -6.7 %
Dividend Yield
Gross Profit TTM 74 214 000 USD
Earnings Share -3.95 USD
Diluted Eps TTM -3.95 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 672.2355
Price Sales TTM 531.9625
Enterprise Value EBITDA -11.0595
Price Book MRQ 123.6828

Financials BBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BBIO

For 52 weeks

12.75 USD 44.32 USD
50 Day MA 31.37 USD
Shares Short Prior Month 13 407 125
200 Day MA 30.45 USD
Short Ratio 7.45
Shares Short 14 280 874
Short Percent 12.19 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics